This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Contents and basic classification information | |||
|---|---|---|---|
| A. Classification codes | ICD-10: Q90.2 / Special Copayment Reduction: V159 / Re-certification cycle: 5 years | B. Synonyms | None |
| C. Adult onset | Identifying balanced translocation carriers within the family is essential; Alzheimer's disease and premature aging are the main complications in adulthood | ||
| 1. History | 2. Causes | 3. Genetics | 4. General epidemiology |
| 5. Pathophysiology | 6. Symptoms | 7. Signs | 8. Screening |
| 9. Diagnosis | 10. Treatment | 11. Prognosis | 12. Prevention |
| 13. References | |||
The history of translocation trisomy 21 begins with the dawn of cytogenetics in the late 1950s and early 1960s. Immediately after Lejeune and colleagues reported standard trisomy in 1959, research groups around the world investigated the cytogenetic diversity of Down syndrome. In 1961, a British research team including Paul Polani reported that in a patient with Down syndrome whose karyotype showed 46 chromosomes, chromosome 21 was attached to another chromosome in a translocation form. This was a landmark discovery showing that Down syndrome does not necessarily have a total of 47 chromosomes.
In the 1960s it was confirmed that the partner chromosomes of the translocation were mostly acrocentric chromosomes such as chromosomes 13, 14, and 15, and this type of translocation was named Robertsonian translocation. The term derives from William Robertson, who first described the phenomenon of centric fusion in insect chromosomes in 1916. Through the 1960s–1970s, chromosome testing of the parents and families of patients with translocation Down syndrome established clinically that when one parent is a balanced Robertsonian translocation carrier, the risk of recurrence of Down syndrome in children is greatly increased.
With the introduction of high-resolution G-banding karyotype analysis in the 1980s, the translocation junction and the chromosomal segments involved could be defined more precisely. In the 1990s, FISH made it possible to confirm the gene content of the translocated segment at the molecular level. In the 21st century, chromosomal microarray and NGS are used for sequence analysis of translocation junctions and for assessing the effect of the genes involved. Translocation Down syndrome is now established as a clinical subtype in which family history and genetic counseling are important, distinct from standard trisomy.
In Korea, as cytogenetic testing spread from the 1970s, family cases of translocation Down syndrome began to be reported, and genetic counseling for balanced Robertsonian translocation carriers and preimplantation genetic testing (PGT-SR) are now established as standard management guidelines.
Translocation trisomy 21 (Q90.2) is the form in which trisomy arises because all or most of the long arm (q arm) of chromosome 21 is fused to another acrocentric chromosome by Robertsonian translocation. Robertsonian translocation refers to a translocation in which two acrocentric chromosomes (chromosomes 13, 14, 15, 21, 22) with short or nearly absent short arms (p arms) join near the centromere to form a single chromosome.
About 75–80% of translocation Down syndrome is due to the Robertsonian translocation rob(14;21) between chromosomes 14 and 21. A balanced carrier has 1 normal chromosome 14, 1 normal chromosome 21, and 1 rob(14;21), for a total of 45 chromosomes, and the karyotype is written as 45,XX,rob(14;21) or 45,XY,rob(14;21). When this carrier forms an unbalanced gamete in meiosis, a child with rob(14;21) + a normal chromosome 21 has 46 chromosomes but three copies of the long arm of chromosome 21, that is, an unbalanced translocation, which is translocation Down syndrome.
About 5% of translocation Down syndrome is of the iso(21q) or rob(21;21) form, in which two chromosomes 21 are joined at the centromere. A rob(21;21) balanced carrier has 45 chromosomes, and in this case, because in meiosis a gamete must receive either rob(21;21) or a normal chromosome 21, all zygotes become trisomy 21 or monosomy 21, and a child with a normal phenotype is impossible. This is clinically very important genetic counseling information.
Translocations with other acrocentric chromosomes, such as rob(13;21), rob(15;21), and rob(21;22), are also rarely reported. Very rarely there are non-Robertsonian translocations, that is, forms in which part or all of the long arm of chromosome 21 is inserted into, or reciprocally exchanged with, a non-acrocentric chromosome.
About 25% of translocation Down syndrome is due to a sporadic (de novo) translocation with normal parental karyotypes, and the remaining about 75% have a parent who is a balanced translocation carrier. This is the most important clinical difference from standard trisomy (almost all sporadic).
The karyotype of translocation trisomy 21 has a total of 46 chromosomes, but taking rob(14;21) as an example it is 46,XX,rob(14;21),+21 or 46,XY,rob(14;21),+21. The Robertsonian translocation fragment is also written as der(14;21). Although the chromosome number of 46 appears normal, three sets of the long arm of chromosome 21 are actually present (1 in the rob and 2 in the normal chromosomes 21), producing a gene dosage imbalance.
When a rob(14;21) balanced carrier (45 chromosomes) undergoes meiosis, the Robertsonian translocation chromosome forms a trivalent during meiosis, and three segregation patterns are possible.
Theoretically, one third of the children of a balanced carrier mother would be expected to have translocation Down syndrome, but the actual risk is low. According to clinical observation, the risk of a Down syndrome birth is about 10–15% for a maternal rob(14;21) carrier and about 2–5% for a paternal carrier, with the paternal risk lower than the maternal. This is presumed to be because unbalanced embryos are selectively lost before implantation or in early pregnancy. For rob(21;21) carriers the risk is theoretically 100%, so the birth of a child with a normal phenotype is impossible.
When both parental karyotypes are normal and a child has de novo translocation Down syndrome, the recurrence risk in the next pregnancy is low (less than about 1%). However, karyotype analysis of both parents is essential for confirmation.
The clinical phenotype of translocation Down syndrome is almost identical to that of standard trisomy. This is because a translocation that includes the entire long arm of chromosome 21 produces the same gene dosage imbalance (three-fold). However, if the chromosome 21 segment included in the translocation is partial, only some genes have three-fold dosage, and a partial Down syndrome phenotype may appear, but this is rare.
Translocation Down syndrome (Q90.2) accounts for about 3–4% of all Down syndrome. The absolute birth frequency is estimated at about 1/20,000–1/25,000. Unlike standard trisomy, the translocation form occurs regardless of maternal age, and its proportion is actually relatively higher in young mothers.
While the incidence of standard trisomy rises sharply with increasing maternal age, translocation Down syndrome has no maternal age effect, because its cause is not maternal meiotic nondisjunction directly but a segregation error in meiosis in a Robertsonian translocation carrier. Therefore, when Down syndrome is diagnosed in a young mother under age 35, the possibility of the translocation form must be considered.
Balanced Robertsonian translocation is a relatively common balanced chromosomal abnormality, present in the general population at a frequency of about 1/1,000. Among these, rob(13;14) is the most common (about 75% of all Robertsonian translocations) and rob(14;21) is the second most common (about 10%). Ethnic differences are not large, and similar frequencies are reported in East Asia including Korea.
Translocation Down syndrome shows the same excess chromosome 21 signal on NIPT as standard trisomy, so it can be detected by NIPT. However, NIPT cannot distinguish the cytogenetic subtypes of trisomy (standard/translocation/mosaic), so invasive testing for confirmation followed by karyotype analysis without fail is needed. Without karyotype analysis it is not possible to know whether it is the translocation form, and there is a risk that family genetic counseling will be omitted.
The formation of Robertsonian translocation is known to result from recombination between ribosomal DNA (rDNA) repeat sequences on the short arms of two acrocentric chromosomes. Acrocentric chromosomes contain rDNA on their short arms and are spatially close to each other around the nucleolus in the nucleus. This proximity promotes non-allelic homologous recombination (NAHR) and induces the formation of Robertsonian translocation.
After double-strand breaks (DSBs) occur in the proximal short arms near the centromeres of two acrocentric chromosomes, the two chromosomes join into one by homologous recombination. As a result of this joining, the short arms (short fragments containing rDNA) are lost, and the two long arms are connected into one chromosome. The lost short arms contain only ribosomal genes, which are present in multiple copies on other acrocentric chromosomes as well, so loss of the short arms has no direct effect on the phenotype. Therefore, rob(14;21) balanced carriers have a normal phenotype.
In meiosis of a balanced carrier, when rob(14;21) + a normal chromosome 21 enter the same gamete, after fertilization the child has rob(14;21) + two normal chromosomes 21 + a normal chromosome 14, so the long arm of chromosome 21 is present in three copies. This creates the same gene dosage imbalance as standard trisomy and causes the Down syndrome phenotype. Genes on the long arm of chromosome 21 such as DYRK1A, APP, RCAN1, and SOD1 are expressed at three-fold dosage, causing the same multisystem dysfunction.
The possibility that short-arm genes (other than rDNA) are disrupted at the Robertsonian translocation junction is very low. However, rarely, when the translocation breakpoint forms at an atypical location or functional genes are included in the short arm, an unexpected additional phenotype may appear. To exclude this, chromosomal microarray is used as a complement in suspected cases.
The risk of forming unbalanced gametes in rob(14;21) carriers depends on the segregation pattern of the trivalent structure during meiosis. The reason the frequency of unbalanced gametes is higher in maternal carriers than in paternal carriers is explained by stronger selection pressure against unbalanced gametes during spermatogenesis (sperm-egg competition, loss before implantation).
The clinical symptoms of translocation Down syndrome (Q90.2) are substantially identical to those of standard trisomy (Q90.0). The complete three-fold dosage of the long arm of chromosome 21 produces the same multisystem phenotype. This subtype is distinguished not because of differences in clinical symptoms but because of the need for assessment of familial recurrence risk and genetic counseling.
Intellectual disability occurs in almost all patients, with an IQ distribution (40–70) equivalent to that of standard trisomy. Delayed language development, reduced processing speed, and weakened short-term auditory memory are characteristic. As a behavioral phenotype, a sociable disposition, musical sensitivity, and a compliant temperament are characteristically described, but individual differences are large. Seizures, infantile spasms, etc. may also occur.
Atrioventricular septal defect (AVSD), ventricular septal defect (VSD), atrial septal defect (ASD), tetralogy of Fallot, etc. occur at the same frequency as in standard trisomy. After the diagnosis is confirmed, echocardiography must be performed to evaluate for cardiac malformations.
Duodenal atresia, Hirschsprung disease, anorectal malformations, and gastroesophageal reflux occur at a frequency similar to that of standard trisomy. Testing to identify gastrointestinal malformations in the neonatal period is needed.
Recurrent infections, autoimmune thyroiditis, celiac disease, increased risk of rheumatic disease, transient abnormal myelopoiesis (TAM), acute lymphoblastic leukemia (ALL), and increased risk of acute megakaryoblastic leukemia (AMKL) are the same as in standard trisomy.
Accumulation of Alzheimer's pathology and the onset of clinical dementia, hypothyroidism and diabetes, obesity, and premature menopause occur after the 40s. Continued multidisciplinary specialist follow-up is needed in adulthood as well.
The clinical signs of translocation Down syndrome are indistinguishable from those of standard trisomy. Therefore, it is not possible to tell whether it is the translocation form from clinical signs alone, and cytogenetic karyotype analysis is essential.
In the neonatal period, characteristic findings appear such as upslanting palpebral fissures, epicanthal folds, Brushfield spots, hypotonia, a single palmar crease, a flat nasal bridge, a short neck, and small ears. Signs related to cardiac malformations such as feeding difficulty, cyanosis, and tachypnea may also appear.
Delays are observed in motor development, language development, and cognitive development. The pattern of developmental delay is similar to that of standard trisomy.
The most important additional clinical information in translocation Down syndrome is the family history. If there is a family history of Down syndrome or chromosomal abnormalities such as recurrent miscarriage and infertility among siblings, parents, or grandparents, the likelihood of the translocation form increases, and parental karyotype analysis is essential. Because the likelihood of the translocation form is also high when Down syndrome occurs in a young mother (<35 years), confirmation should not be concluded without karyotype analysis.
Skeletal signs such as atlantoaxial instability, ligamentous laxity, flat feet, and scoliosis may also appear as in standard trisomy and require regular evaluation.
Prenatal screening for translocation Down syndrome operates in the same way as the standard trisomy screening system, but karyotype analysis is essential to distinguish the subtype.
Standard Down syndrome screening tools such as NIPT, first-trimester combined screening, and quad screening detect an excess of chromosome 21, so positive results are also seen in the translocation form. However, because NIPT cannot distinguish subtypes, when there is a NIPT-positive result suspicious for Down syndrome, karyotype analysis must be performed together with invasive confirmatory testing.
Couples identified as balanced Robertsonian translocation carriers should receive genetic counseling in early pregnancy or at the pregnancy planning stage. Balanced embryos can be selected through preimplantation genetic testing (PGT-SR), or early confirmation is possible by CVS or amniocentesis in early pregnancy.
When the parents of a child with translocation Down syndrome are identified as balanced translocation carriers, siblings with a normal phenotype may also be balanced translocation carriers, so confirmatory testing is recommended. In particular, identifying carriers among siblings who have reached childbearing age is important.
After diagnosis, regular monitoring of thyroid function, hearing, vision, the heart, and atlantoaxial instability is performed, and continued follow-up including evaluation for Alzheimer's disease in adulthood is carried out.
The most important point in confirming translocation Down syndrome is that karyotype analysis is performed in every case of confirmed Down syndrome to distinguish the standard, translocation, and mosaic forms.
Karyotype analysis is performed on whole-blood lymphocytes or amniotic/chorionic cells. In translocation Down syndrome, a total of 46 chromosomes is seen, but chromosome 14 (or another acrocentric chromosome) is abnormally large or has a doubled region, so the translocation partner chromosome (der chromosome) is recognized. Examples of karyotype reports: 46,XX,rob(14;21),+21 or 46,XY,der(14;21)(q10;q10),+21.
When a patient with translocation Down syndrome is identified, karyotype analysis of both parents must be performed to determine whether either is a balanced Robertsonian translocation carrier. This is essential for estimating recurrence risk and for genetic counseling. If one of the parents is identified as a carrier, carrier testing is also recommended for siblings and the extended family.
FISH can confirm that the translocated segment contains chromosome 21 long-arm sequences. Microarray (SNP array or CGH array) is useful for quantitatively confirming copy number variation of the genomic segment included in the translocation and for excluding unexpected additional genomic abnormalities.
When the chromosome 21 segment included in the translocation is not the entire long arm of chromosome 21, a partial Down syndrome phenotype may appear, so confirming the segment size by microarray or FISH is recommended. Analysis of the correlation between phenotype and the size of the translocated segment provides important information for research on the Down syndrome critical region (DSCR).
When PGT-SR is performed during in vitro fertilization in balanced carrier parents, embryos for transfer can be selected by distinguishing balanced translocation (carrier) and euploid (normal) embryos from unbalanced translocation embryos (translocation Down syndrome or partial monosomy). PGT based on high-resolution SNP microarray provides reliable results even at the single-cell level.
Clinical management of translocation Down syndrome is the same as for standard trisomy and follows a multidisciplinary approach to accompanying complications. What is additionally important in this subtype is family genetic counseling and appropriate support for family members who are carriers.
For congenital heart disease (AVSD, VSD, etc.), early surgical correction is the principle, and gastrointestinal malformations (duodenal atresia, Hirschsprung disease, etc.) are also treated according to surgical indications. It is important to establish a specialist consultation system for each organ abnormality.
Developmental potential is maximized through early intervention programs such as speech therapy, occupational therapy, physical therapy, and special education. Family-centred care is recommended, and parent education and support are also important elements.
Levothyroxine treatment for hypothyroidism, nutritional counseling for obesity prevention, and diabetes monitoring are performed.
Family members identified as balanced translocation carriers are provided with non-directive genetic counseling on recurrence risk, preimplantation genetic testing, and prenatal diagnosis options. Careful counseling is required for rob(21;21) carriers, including that the birth of a child with a normal phenotype is impossible. Psychological support for the whole family and connection to a support group are also recommended.
This includes adult Alzheimer's disease screening, annual evaluation of thyroid function, mental health monitoring, and support for employment and social integration.
The prognosis of translocation Down syndrome is similar to that of standard trisomy. Because the entire long arm of chromosome 21 is present in three copies, the scale of the gene dosage imbalance is the same, and therefore long-term prognosis such as intellectual disability, life expectancy, and Alzheimer's disease risk is also indistinguishable from the standard form.
An average life expectancy of 60 years or more is now expected, and complications related to congenital heart disease, recurrent respiratory infections, leukemia, and Alzheimer's dementia are the main causes of death. Life expectancy can be maximized through active management of complications and multidisciplinary follow-up.
Parents and siblings identified as balanced translocation carriers have a normal phenotype themselves, but the risk of having a child with Down syndrome or an unbalanced translocation in future pregnancies is markedly high. Active genetic counseling and reproductive planning support for this are the key to improving prognosis (preventing recurrence).
The key to preventing translocation Down syndrome is identifying balanced Robertsonian translocation carriers and reproductive planning accordingly. Unlike the prenatal screening strategy for standard trisomy, the translocation form is independent of maternal age, so the first prevention strategy is to perform karyotype analysis in every confirmed case of Down syndrome to determine whether it is the translocation form.
When a patient with translocation Down syndrome occurs, parental karyotype analysis is used to determine carrier status, and if a carrier is identified, karyotype analysis of the extended family (grandparents, siblings, etc.) is recommended. Balanced translocation carrier status is also evaluated when there is a history of recurrent miscarriage or Down syndrome in the family.
When balanced carrier couples undergo in vitro fertilization, unbalanced translocation embryos (at risk of translocation Down syndrome) are excluded through PGT-SR, and balanced or normal embryos are selected for transfer. For rob(21;21) carriers, the birth of a normal child is impossible, so alternatives such as donor gametes or adoption should be discussed.
In pregnant women who are balanced carriers, fetal karyotype analysis is performed by CVS in early pregnancy (10–13 weeks) or amniocentesis in mid-pregnancy (15–20 weeks) to determine early whether the fetus has unbalanced translocation Down syndrome. Non-directive genetic counseling supports informed decisions.
After birth, complications are detected and treated early through standard monitoring according to Down syndrome management guidelines (echocardiography, thyroid function, hearing, vision, atlantoaxial evaluation, etc.) to improve quality of life.